ESTRO 2025 - Abstract Book

S1758

Clinical – Upper GI

ESTRO 2025

Results:

Fifty-five patients were treated, with a median follow-up of 13.54 months. The primary tumors were predominantly lung cancer (74.5%), with adenocarcinoma being the most common histology (52.7%). Over 60% of patients had only 1 or 2 metastases. SBRT was delivered at a mean dose of 47.5 Gy, with 58% receiving a biologically effective dose (BED) greater than 100. The overall response rate was 60% (20% complete response [CR], 40% partial response [PR]). LC was achieved in 82.4% of cases, with a median duration of 58.4 months (95% CI: 46.3-71.4). The median OS was 25.6 months (95% CI: 15.6-35.6). Significant associations were found between OS and RECIST response, LC, BED, and number of metastases. Higher survival was linked to a BED >100 (p < 0.003) and fewer than 1 metastasis (p < 0.005). Only -% present grade I-II toxicity, no grade ≥3 toxicity was found.

Conclusion: SBRT with ablative doses (BED > 100) is an effective and safe option for treating adrenal metastases in oligometastatic patients.

Keywords: SBRT, adrenal, oligometastatic

References: König L, Häfner MF, Katayama S, Koerber SA, Tonndorf-Martini E, Bernhardt D, et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiation Oncology. 2020 Dec 4;15(1):30. Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, et al. Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. International Journal of Radiation Oncology*Biology*Physics. 2020 May;107(1):48–61.